Average Insider

Where insiders trade, we follow

$PEPG
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Healthcare
Sector
Biotechnology
Industry
James G. McArthur
CEO
79
Employees
$3.88
Current Price
$444.73M
Market Cap
52W Low$1.31
Current$3.8839.6% above low, 60.4% below high
52W High$7.80

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys11$43,125,000.008,625,000All Buys
Sells00--
2 weeksBuys11$43,125,000.008,625,000All Buys
Sells00--
1 monthBuys11$43,125,000.008,625,000All Buys
Sells00--
2 monthsBuys11$43,125,000.008,625,000All Buys
Sells00--
3 monthsBuys11$43,125,000.008,625,000All Buys
Sells00--
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Nov 13, 2026
RA CAPITAL MANAGEMENT, L.P.
Director
Purchase8,625,000$5.00$43,125,000.00View Details
7 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Nov 11, 2026
EPS
Estimated-$0.27
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Nov 10, 2026
EPS
Estimated-$0.27
Actual-$0.28
Miss
Revenue
EstimatedN/A
ActualN/A
1 more earnings records available โ€” create a free account to see 12 months of history
Version: v26.11.1